Clinical trial · Observational
Genetic Mutation in Epithelial Ovarian Cancer
Overall Perspective on the Characteristics of Genetic Mutation in Chinese Patients of Epithelial Ovarian Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Little is known about the characteristics of genetic mutation in a large multi-gene panel in epithelial ovarian cancer. This study is to explore the targeted genetic mutations via a multi-gene panel, which consists of more than 500 hundred genes. The mutation characteristics are to be revealed in single nucleotide variants, copy number variations, insertion-deletion variations, and genomic structural variations. The total mutation burden (TMB) will be calculated. The status of microsatellite instability, expression of PD-1 and PD-L1 antibodies are also tested. These findings will be studies in association with the patients' prognosis and sensitivity to platinum-based chemotherapy.
Conditions
Conditions (9)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Copy Number Variation | — | UNRESOLVED | — |
| Epithelial Ovarian Cancer | Ovarian Carcinoma | ALIAS | 0.90 |
| Genomic Structural Variation | — | UNRESOLVED | — |
| Insertion-deletion Variation | — | UNRESOLVED | — |
| Microsatellite Instability | — | UNRESOLVED | — |
| Nucleotide Variant | — | UNRESOLVED | — |
| PD-1 | — | UNRESOLVED | — |
| PD-L1 | — | UNRESOLVED | — |
| Total Mutation Burden | — | UNRESOLVED |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| A multi-gene panel testing | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Frequency of genetic mutations
- timeFrame
- Two years
- description
- Frequency of various genetic mutations among recruited patients
Secondary outcomes (3)
- measure
- Total mutation burden
- timeFrame
- Two years
- description
- Total mutation burden calculated in definite patient
- measure
- Frequency of microsatellite Instability
- timeFrame
- Two years
- description
- Microsatellite Instability in definite patient
- measure
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Aged 18 years or older * Pathology confirmed of recurrent cervical adenocarcinoma, squamous carcinoma or adenosquamous carcinoma * With available materials for analysis * With detailed clinicopathological information * Given consent to participate the trial Exclusion Criteria: * Not meeting all of the inclusion criteria
References
Publications (0)
Data not yet available